UGN-301

· UroGen Pharma Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UGN-301, covering 2026-01-14 to 2026-01-14. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]

See pricing